32300 Federal Register / Vol. 83, No. 134 / Thursday, July 12, 2018 / Notices 

ADDRESSES: Teleconference Number: 1– 

888–790–3409, passcode: 3250534. 

FOR FURTHER INFORMATION CONTACT: Erin 

Stone, M.A., HICPAC, Division of 

Healthcare Quality Promotion, NCEZID, 

CDC, 1600 Clifton Road NE, Mailstop 

A–31, Atlanta, Georgia 30333; 

Telephone (404) 639–4045, Email: 

HICPAC@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Committee is charged 

with providing advice and guidance to 

the Director, Division of Healthcare 

Quality Promotion (DHQP), the Director, 

National Center for Emerging and 

Zoonotic Infectious Diseases (NCEZID), 

the Director, CDC, the Secretary, Health 

and Human Services regarding (1) the 

practice of healthcare infection 

prevention and control; (2) strategies for 

surveillance, prevention, and control of 

infections, antimicrobial resistance, and 

related events in settings where 

healthcare is provided; and (3) periodic 

updating of CDC guidelines and other 

policy statements regarding prevention 

of healthcare-associated infections and 

healthcare-related conditions. 

Matters to be Considered: The agenda 

will include discussions on updates 

from the guidelines for infection 

prevention in healthcare personnel 

workgroup and the guidelines for 

infection prevention in patients of 

neonatal intensive care units 

workgroup. Agenda items are subject to 

change as priorities dictate. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri A. Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–14930 Filed 7–11–18; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

Notice of Hearing: Reconsideration of 

Disapproval Washington Medicaid 

State Plan Amendment (SPA) 17–0027 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice of hearing: 

Reconsideration of disapproval. 

SUMMARY: This notice announces an 

administrative hearing to be held on 

August 9, 2018, at the Department of 

Health and Human Services, Centers for 

Medicare & Medicaid Services, Division 

of Medicaid & Children’s Health, Seattle 

Regional Office, 701 Fifth Avenue, Suite 

1600, Seattle, WA 98104 to reconsider 

CMS’ decision to disapprove 

Washington’s Medicaid SPA 17–0027. 

DATES: Closing Date: Requests to 

participate in the hearing as a party 

must be received by the presiding 

officer by July 27, 2018. 

FOR FURTHER INFORMATION CONTACT: 

Benjamin R. Cohen, Presiding Officer, 

CMS, 2520 Lord Baltimore Drive, Suite 

L, Baltimore, Maryland 21244, 

Telephone: (410) 786–3169. 

SUPPLEMENTARY INFORMATION: This 

notice announces an administrative 

hearing to reconsider CMS’ decision to 

disapprove Washington’s Medicaid state 

plan amendment (SPA) 17–0027, which 

was submitted to the Centers for 

Medicare & Medicaid Services (CMS) on 

August 22, 2017 and disapproved on 

May 14, 2018. This SPA requested CMS 

approval to add coverage and 

reimbursement of services provided by 

Dental Health Aide Therapists (DHATs) 

under the Other Licensed Practitioner 

(OLP) benefit. Specifically, SPA 17– 

0027 proposed the coverage and 

reimbursement of services provided by 

DHATs only when furnished in a 

practice setting within the boundaries of 

a tribal reservation and only when 

operated by an Indian health program, 

and proposed to make coverage of 

DHAT services available only to 

members of a federally recognized tribe 

or those otherwise eligible for services 

under Indian Health Service criteria. 

Washington would, therefore, not 

permit Medicaid beneficiaries to receive 

Medicaid coverage for DHAT services if 

they are not members of a federally 

recognized tribe or otherwise eligible for 

services under Indian Health Service 

criteria. 

The issues to be considered at the 

hearing are whether Washington SPA 

17–0027 is inconsistent with the 

requirements of: 

• Section 1902(a)(23) of the Social 

Security Act (the Act) because it would 

restrict access to services provided by a 

DHAT to a limited group of 

beneficiaries, and it would also prevent 

beneficiaries from receiving DHAT 

services from similarly qualified dental 

services providers that provide services 

outside the boundaries of a tribal 

reservation or that are not Indian health 

programs. 

• Section 1902(a)(10)(A) of the Act 

because it was unclear whether DHATs 

must be supervised by a licensed 

professional consistent with the 

requirements of the OLP benefit, and 

because CMS was therefore unable to 

determine whether DHAT services are 

‘‘medical assistance’’ consistent with 

1902(a)(10)(A) and 1905 of the Act. 

Section 1116 of the Act and federal 

regulations at 42 CFR part 430 establish 

Department procedures that provide an 

administrative hearing for 

reconsideration of a disapproval of a 

state plan or plan amendment. CMS is 

required to publish in the Federal 

Register a copy of the notice to a state 

Medicaid agency that informs the 

agency of the time and place of the 

hearing, and the issues to be considered. 

If we subsequently notify the state 

Medicaid agency of additional issues 

that will be considered at the hearing, 

we will also publish that notice in the 

Federal Register. 

Any individual or group that wants to 

participate in the hearing as a party 

must petition the presiding officer 

within 15 days after publication of this 

notice, in accordance with the 

requirements contained at 42 CFR 

430.76(b)(2). Any interested person or 

organization that wants to participate as 

amicus curiae must petition the 

presiding officer before the hearing 

begins in accordance with the 

requirements contained at 42 CFR 

430.76(c). If the hearing is later 

rescheduled, the presiding officer will 

notify all participants. 

The notice to Washington announcing 

an administrative hearing to reconsider 

the disapproval of its SPA reads as 

follows: 

Ms. MaryAnne Lindeblad 

Director 

State of Washington, Health Care Authority 

626 8th Avenue PO Box 45502 

Olympia, WA 98504–5050 

Dear Ms. Lindeblad: 

I am responding to your June 8, 2018 

request for reconsideration of the decision to 

disapprove Washington’s State Plan 

amendment (SPA) 17–0027. Washington SPA 

17–0027 was submitted to the Centers for 

Medicare & Medicaid Services (CMS) on 

August 22, 2017, and disapproved on May 

14, 2018. I am scheduling a hearing on your 

request for reconsideration to be held on 

August 9, 2018, at the Department of Health 

and Human Services, Centers for Medicare & 

Medicaid Services, Division of Medicaid & 

Children’s Health, Seattle Regional Office, 

701 Fifth Avenue, Suite 1600, Seattle, WA 

98104. 

I am designating Mr. Benjamin R. Cohen as 

the presiding officer. If these arrangements 

present any problems, please contact Mr. 

Cohen at (410) 786–3169. In order to 

facilitate any communication that may be 

necessary between the parties prior to the 

hearing, please notify the presiding officer to 


amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 134 / Thursday, July 12, 2018 / Notices 32301 

indicate acceptability of the hearing date that 

has been scheduled and provide names of the 

individuals who will represent the State at 

the hearing. If the hearing date is not 

acceptable, Mr. Cohen can set another date 

mutually agreeable to the parties. The 

hearing will be governed by the procedures 

prescribed by federal regulations at 42 CFR 

Part 430. 

This SPA requested CMS approval to add 

coverage and reimbursement of services 

provided by Dental Health Aide Therapists 

(DHATs) under the Other Licensed 

Practitioner (OLP) benefit. Specifically, SPA 

17–0027 proposed the coverage and 

reimbursement of services provided by 

DHATs only when furnished in a practice 

setting within the boundaries of a tribal 

reservation and only when operated by an 

Indian health program, and proposed to make 

coverage of DHAT services available only to 

members of a federally recognized tribe or 

those otherwise eligible for services under 

Indian Health Service criteria. Washington 

would, therefore, not permit Medicaid 

beneficiaries to receive Medicaid coverage for 

DHAT services if they are not members of a 

federally recognized tribe or otherwise 

eligible for services under Indian Health 

Service criteria. 

The issues to be considered at the hearing 

are whether Washington SPA 17–0027 is 

inconsistent with the requirements of: 

• Section 1902(a)(23) of the Social Security 

Act (the Act) because it would restrict access 

to services provided by a DHAT to a limited 

group of beneficiaries, and it would also 

prevent beneficiaries from receiving DHAT 

services from similarly qualified dental 

services providers that provide services 

outside the boundaries of a tribal reservation 

or that are not Indian health programs. 

• Section 1902(a)(10)(A) of the Act because 

it was unclear whether DHATs must be 

supervised by a licensed professional 

consistent with the requirements of the OLP 

benefit, and because CMS was therefore 

unable to determine whether DHAT services 

are ‘‘medical assistance’’ consistent with 

1902(a)(10)(A) and 1905 of the Act. 

In the event that CMS and the State come 

to agreement on resolution of the issues 

which formed the basis for disapproval, this 

SPA may be moved to approval prior to the 

scheduled hearing. 

Sincerely, 

Seema Verma 

Administrator 

Section 1116 of the Social Security Act (42 

U.S.C. section 1316; 42 CFR section 430.18) 

(Catalog of Federal Domestic Assistance 

program No. 13.714. Medicaid Assistance 

Program.) 

Dated: July 6, 2018. 

Seema Verma, 

Administrator, Centers for Medicare & 

Medicaid Services. 

[FR Doc. 2018–14876 Filed 7–6–18; 4:15 pm] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–2642] 

Advisory Committee; Science Advisory 

Board to the National Center for 

Toxicological Research; Renewal 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; renewal of advisory 

committee. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

renewal of the Science Advisory Board 

(the Board) to the National Center for 

Toxicological Research (NCTR) by the 

Commissioner of Food and Drugs (the 

Commissioner). The Commissioner has 

determined that it is in the public 

interest to renew the Board to the NCTR 

for an additional 2 years beyond the 

charter expiration date. The new charter 

will be in effect until June 2, 2020. 

DATES: Authority for the Board to the 

NCTR expired on June 2, 2018; 

however, the Commissioner formally 

determined that renewal is in the public 

interest. 

FOR FURTHER INFORMATION CONTACT: 

Donna L. Mendrick, National Center for 

Toxicological Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 2208, Silver Spring, 

MD 20993–0002, 301–796–8892, 

donna.mendrick@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to 41 CFR 102–3.65 and approval by the 

Department of Health and Human 

Services pursuant to 45 CFR part 11 and 

by the General Services Administration, 

FDA is announcing the renewal of the 

Board to the NCTR. The Board is a 

discretionary Federal advisory 

committee established to provide advice 

to the Commissioner. The Board to the 

NCTR advises the Commissioner or 

designee in discharging responsibilities 

as they relate to helping to ensure safe 

and effective drugs for human use and, 

as required, any other product for which 

FDA has regulatory responsibility. The 

Board advises the NCTR Director in 

establishing, implementing, and 

evaluating the research programs that 

assist the Commissioner in fulfilling 

regulatory responsibilities. The Board 

provides an extra-agency review in 

ensuring that the research programs at 

NCTR are scientifically sound and 

pertinent. 

The Board shall consist of a core of 

nine voting members including the 

Chair. Members and the Chair are 

selected by the Commissioner or 

designee from among authorities 

knowledgeable in the fields of 

toxicological research. Members will be 

invited to serve for overlapping terms of 

up to 4 years. Almost all non-Federal 

members of this Board serve as Special 

Government Employees. The core of 

voting members may include one 

technically qualified member, selected 

by the Commissioner or designee, who 

is identified with consumer interests 

and is recommended by either a 

consortium of consumer-oriented 

organizations or other interested 

persons. 

Further information regarding the 

most recent charter and other 

information can be found at https://

www.fda.gov/AdvisoryCommittees/ 

CommitteesMeetingMaterials/ 

ToxicologicalResearch/ucm148166.htm 

or by contacting the Designated Federal 

Officer (see FOR FURTHER INFORMATION

CONTACT). In light of the fact that no 

change has been made to the committee 

name or description of duties, no 

amendment will be made to 21 CFR 

14.100. 

This document is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app.). For general information 

related to FDA advisory committees, 

please check https://www.fda.gov/ 

AdvisoryCommittees/default.htm. 

Dated: July 9, 2018. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2018–14943 Filed 7–11–18; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–2565] 

Advisory Committee; 

Psychopharmacologic Drugs Advisory 

Committee; Renewal 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; renewal of advisory 

committee. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

renewal of the Psychopharmacologic 

Drugs Advisory Committee by the 

Commissioner of Food and Drugs (the 

Commissioner). The Commissioner has 

determined that it is in the public 

interest to renew the 

Psychopharmacologic Drugs Advisory 

Committee for an additional 2 years 

beyond the charter expiration date. The 

new charter will be in effect until June 

4, 2020. 


amozie on DSK3GDR082PROD with NOTICES1